Please assess the completion status of the following clinical trial:

Trial Title: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Prior diagnosis of multiple myeloma according to IMWG diagnostic criteria.~* Measurable disease at screening.~* Has received at least 3 but not more than 5 prior lines of multiple myeloma treatment, including proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapies.~* Eastern Cooperative Oncology Group performance status of 0 or 1.~* Willing to avoid pregnancy or fathering children.~* Willing to provide fresh and archival bone marrow aspiration and biopsy tissue.~Exclusion Criteria:~* Receipt of any of the following treatment within the indicated interval before the first administration of study drug:~  * Anti-myeloma treatment within 2 weeks or 5 half-lives (whichever is longer).~ * Investigational drug (including investigational vaccines) or invasive investigational medical device within 4 weeks.~ * Autologous stem cell transplant within 12 weeks, or allogeneic stem cell transplant at any time.~ * Plasmapheresis within 4 weeks.~ * Radiation therapy within 2 weeks.~ * Major surgery within 2 weeks, or inadequate recovery from an earlier surgery, or surgery planned during the time the participant is expected to participate in the study or within 2 weeks after the last dose of study treatment.~* Toxicity ≥ Grade 2 from previous anti-myeloma therapy except for stable chronic toxicities (≤ Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.~* Known additional malignancy (other than multiple myeloma) that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.~* Laboratory values at screening outside the protocol-defined range.~* Significant concurrent, uncontrolled medical condition including but not limited to known chronic obstructive pulmonary disease (COPD), persistent asthma, or history of asthma within the past 2 years; chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment; acute diffuse infiltrative pulmonary disease; clinically significant or uncontrolled cardiac disease.~* Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or amyloidosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB001158 + daratumumab SC (Type: EXPERIMENTAL): INCB001158 + daratumumab
- Daratumumab monotherapy and crossover to INC001158+ daratumumab SC (Type: ACTIVE_COMPARATOR): Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
- INCB001158 monotherapy and crossover to INC001158+ daratumumab SC (Type: EXPERIMENTAL): INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues